Concepedia

Edward Fox

EF

Statistics

Publications

68

Citations

7.4K

H-Index

39

Active since

1996

Affiliations

Central Texas Neurology Consultants(Current)

University of Pennsylvania

Penn State Milton S. Hershey Medical Center

Heinrich Heine University Düsseldorf

University of Cambridge

Edward Fox is an author at Central Texas Neurology Consultants specializing in medicine, multiple sclerosis, and multiple sclerosis pharmacotherapy.

ORCID

Publications per year

1996–2024

68

Publications

68

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Jeffrey Cohen, Alasdair Coles, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations

, , +11

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Alasdair Coles, Cary Twyman, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations · Full text

, , +11

Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial

Anthony Traboulsee, Benjamin Greenberg, Jeffrey L. Bennett et al. · The Lancet Neurology · 2020 · 490 citations · Full text

, , +5

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis

Amit Bar‐Or, Jonathan Calkwood, Cathy Chognot et al. · Neurology · 2020 · 339 citations · Full text

, , +17

Alemtuzumab CARE-MS II 5-year follow-up

Alasdair Coles, Jeffrey Cohen, Edward Fox et al. · Neurology · 2017 · 274 citations · Full text

, , +15

1–5 of 68